好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

2025 Annual Meeting | C164 - Myelin Oligodendrocyte Glycoprotein Antibody Disorders (MOGAD)

Tuesday 04/08/25
03:30 PM - 05:30 PM PDT Add To Calendar
San Diego Convention Center | 6A
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Giulia Fadda, MD
Multiple Sclerosis
Participants should learn to identify MOGAD diagnostic criteria and red flags that distinguish it from other neuroinflammatory conditions; explore the clinical course and prognosis of MOGAD, including age-specific outcomes, and assess disability risks; and review current and emerging therapies, gaining the skills to select appropriate treatments based on patient factors and to evaluate treatment efficacy and safety, enhancing clinical decision-making in MOGAD care.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement
Advanced
Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student
Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
03:30 PM - 03:35 PM PDT Introduction Welcome
Giulia Fadda, MD
03:35 PM - 04:00 PM PDT Speaker MOGAD Diagnostic Criteria and Red Flags
Giulia Fadda, MD
04:00 PM - 04:35 PM PDT Speaker Clinical Course and Prognosis
Jacqueline Palace
04:35 PM - 05:10 PM PDT Speaker Current and Emerging Therapies
Michael Levy, MD, PhD, FAAN
05:10 PM - 05:30 PM PDT Discussion Discussion
Giulia Fadda, MD, Michael Levy, MD, PhD, FAAN, Jacqueline Palace
Faculty Disclosures
Giulia Fadda, MD Dr. Fadda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen/Horizon Therapeutics. Dr. Fadda has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Novartis.
Michael Levy, MD, PhD, FAAN Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Levy has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Levy has received research support from National Institutes Health.
Jacqueline Palace Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck Serono, Medimmune, Argenx, Janssen, AMgen, UCB, Roche, Novartis, Amplo, Alexion, . Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx, Sanofi. Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Roche, UCB, Alexion, Amgen. Dr. Palace has stock in Astra Zenica. The institution of Dr. Palace has received research support from Roche, AMPLO, Alexion, UCB,. argenx, amgen. Dr. Palace has received intellectual property interests from a discovery or technology relating to health care.